Do Traders Think Aclaris Therapeutics Inc (ACRS) Can Keep Climbing Tuesday?

The market has been high on Aclaris Therapeutics Inc (ACRS) stock recently. ACRS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Aclaris Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ACRS!

See Full ACRS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ACRS Stock Today?

Aclaris Therapeutics Inc (ACRS) stock is trading at $0.90 as of 9:38 AM on Tuesday, Nov 21, a drop of -$0.04, or -4.53% from the previous closing price of $0.94. The stock has traded between $0.86 and $0.90 so far today. Volume today is less active than usual. So far 159,089 shares have traded compared to average volume of 6,445,019 shares. To see InvestorsObserver's Sentiment Score for Aclaris Therapeutics Inc click here.

More About Aclaris Therapeutics Inc

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Click Here to get the full Stock Report for Aclaris Therapeutics Inc stock.